Benzinga | Dec 7, 2021 10:03AM EST

UK's Medicines And Healthcare Products Regulatory Agency Approves XEVUDY, GlaxoSmithKline And Vir Biotechnology's Monoclonal Antibody Treatment For Patients With COVID-19

Brand Institute is proud to announce its successful partnership with GlaxoSmithKline and Vir Biotechnology in developing the brand name XEVUDY(r), a monoclonal antibody therapeutic approved for symptomatic adults and adolescents (12 years of age and older) with acute COVID--19 infection. XEVUDY(r) reduces the risk of hospitalization and death by 79% in high-risk adults with symptoms, based on clinical data.

"The entire Brand Institute and Drug Safety Institute Team congratulates GSK and Vir Biotechnology on the MHRA approval of XEVUDY(r)," said Brand Institute's Chairman and CEO, James L. Dettore. "XEVUDY(r) will surely be an important treatment option in the global fight against COVID-19."

The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) is the first health agency to approve XEVUDY(r). Approval of the product and the brand name by other regulatory agencies will follow their respective guidelines, policies and procedures.